UK – NICE rejects Sanofi’s Cablivi in draft guidelines

NICE has drawn up draft guidelines rejecting Sanofi's Cablivi (caplacizumab) for use alongside plasma exchange and immunosuppression for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP).

Standard care for patients in this setting includes plasma exchange and immunosuppressant medicines, and trial results show that adding Cablivi reduces:

* the time it takes to bring platelet levels back to normal

* the number of plasma exchange treatments needed

* time in hospital and intensive care.

Adding Cablivi could also reduce the long-term complications of acquired TTP and risk of death around the time of an acute episode…